Clinical Trial Update: Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating serologic assay validation, proficiency testing, safety and immunogenicity of a norovirus GI.1/GII.4 bivalent VLP vaccine; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• Norovirus GI.1/GII.4 bivalent virus-like particle vaccine (Norovirus GI.1/GII.4 virus-like particle vaccine)

Snippet

Sponsor: Takeda | Conditions: Norovirus, Healthy Participants | Phase 2 | Status: COMPLETED | Results posted: 2016-10-28